Liver resection for metastatic uveal melanoma: experience from a supra-regional centre and review of literature.
Journal
Melanoma research
ISSN: 1473-5636
Titre abrégé: Melanoma Res
Pays: England
ID NLM: 9109623
Informations de publication
Date de publication:
01 02 2023
01 02 2023
Historique:
pubmed:
22
11
2022
medline:
24
12
2022
entrez:
21
11
2022
Statut:
ppublish
Résumé
Management of liver metastases from uveal melanoma (LMUM) requires multimodal approach. This study describes evolution of liver resection for LMUM, reviewing current literature and institutional outcomes. Records of patients referred to the Melanoma Multi-Disciplinary Team between February 2005 and August 2018 were reviewed. All publications describing surgery for LMUM were identified from PubMed, Embase, and Google Scholar. Thirty-one of 147 patients with LMUM underwent laparoscopic liver biopsy, and 29 (14 females) had liver resections. Nineteen liver resections were performed locally [7 major (≥3 seg), 14 laparoscopic] without major complications or mortality. Overall survival positively correlated with the time from uveal melanoma to LMUM (Spearman's rho rs = 0.859, P < 0.0001). Overall and recurrence-free survivals were comparable following R1 or R0 resections (OS 25 vs. 28 months, P = 0.404; RFS 13 vs. 6 months, P = 0.596). R1 resection cohort had longer lead-time (median 100 vs. 24 months, P = 0.0408). Eleven publications describing liver resection for LMUM were identified and included in the narrative review. Surgery for LMUM is safe and complements multidisciplinary management. Despite heterogeneity in literature, time from diagnosis of uveal melanoma to LMUM remains a key factor affecting survival after liver resection.
Identifiants
pubmed: 36409208
doi: 10.1097/CMR.0000000000000867
pii: 00008390-202302000-00008
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
71-79Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Yonekawa Y, Kim IK. Epidemiology and management of uveal melanoma. Hematol/Oncol Clin 2012; 26:1169–1184.
Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, Crocetti E, et al. EUROCARE Working GroupEUROCARE Working Group. Incidence of uveal melanoma in Europe. Ophthalmology 2007; 114:2309–2315.
Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye 2017; 31:241–257.
Carvajal RD, Schwartz GK, Tezel T, Marr B, Francis JH, Nathan PD. Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol 2017; 101:38–44.
Agarwala SS, Eggermont AM, O’Day S, Zager JS. Metastatic melanoma to the liver: a contemporary and comprehensive review of surgical, systemic, and regional therapeutic options. Cancer 2014; 120:781–789.
Nathan P, Hassel JC, Rutkowski P, Baurain JF, Butler MO, Schlaak M, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021; 385:1196–206.
Aoyama T, Mastrangelo MJ, Berd D, Nathan FE, Shields CL, Shields JA, et al. Protracted survival after resection of metastatic uveal melanoma. Cancer: Interdiscip Int J Am Cancer Soc 2000; 89:1561–1568.
Gomez D, Wetherill C, Cheong J, Jones L, Marshall E, Damato B, et al. The Liverpool uveal melanoma liver metastases pathway: outcome following liver resection. J Surg Oncol 2014; 109:542–547.
Mariani P, Almubarak MM, Kollen M, Wagner M, Plancher C, Audollent R, et al. Radiofrequency ablation and surgical resection of liver metastases from uveal melanoma. Eur J Surg Oncol (EJSO) 2016; 42:706–712.
Servois V, Bouhadiba T, Dureau S, Da Costa C, Almubarak MM, Foucher R, et al. Iterative treatment with surgery and radiofrequency ablation of uveal melanoma liver metastasis: retrospective analysis of a series of very long-term survivors. Eur J Surg Oncol 2019; 45:1717–1722.
Abbott AM, Doepker MP, Kim Y, Perez MC, Gandle C, Thomas KL, et al. Hepatic progression-free and overall survival after regional therapy to the liver for metastatic melanoma. Am J Clin Oncol 2018; 41:747.
Karydis I, Gangi A, Wheater MJ, Choi J, Wilson I, Thomas K, et al. Percutaneous hepatic perfusion with melphalan in uveal melanoma: a safe and effective treatment modality in an orphan disease. J Surg Oncol 2018; 117:1170–1178.
Nathan P, Cohen V, Coupland S, Curtis K, Damato B, Evans J, et al. Uveal melanoma UK national guidelines. Eur J Cancer 2015; 51:2404–2412.
Strasberg SM. Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. J Hepatobiliary Pancreat Surg 2005; 12:351–355.
Clavien PA, Barkun J, De Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009; 250:187–196.
Rowcroft A, Loveday BP, Thomson BN, Banting S, Knowles B. Systematic review of liver directed therapy for uveal melanoma hepatic metastases. HPB 2020; 22:497–505.
Hsueh EC, Essner R, Foshag LJ, Ye X, Wang HJ, Morton DL. Prolonged survival after complete resection of metastases from intraocular melanoma. Cancer: Interdiscip Int J Am Cancer Soc 2004; 100:122–129.
Rivoire M, Kodjikian L, Baldo S, Kaemmerlen P, Négrier S, Grange JD. Treatment of liver metastases from uveal melanoma. Ann Surg Oncol 2005; 12:422–428.
Kodjikian L, Grange JD, Baldo S, Baillif S, Garweg JG, Rivoire M. Prognostic factors of liver metastases from uveal melanoma. Graefe’s Arch Clin Exp Ophthalmol 2005; 243:985–993.
Pawlik TM, Zorzi D, Abdalla EK, Clary BM, Gershenwald JE, Ross MI, et al. Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol 2006; 13:712–720.
Adam R, Chiche L, Aloia T, Elias D, Salmon R, Rivoire M, et al. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1452 patients and development of a prognostic model. Ann Surg 2006; 244:524.
Mariani P, Piperno-Neumann S, Servois V, Berry MG, Dorval T, Plancher C, et al. Surgical management of liver metastases from uveal melanoma: 16 years’ experience at the Institut Curie. Eur J Surg Oncol (EJSO) 2009; 35:1192–1197.
Frenkel S, Nir I, Hendler K, Lotem M, Eid A, Jurim O, et al. Long-term survival of uveal melanoma patients after surgery for liver metastases. Br J Ophthalmol 2009; 93:1042–1046.
de Ridder J, van Walsum M, Verhoef C, Nagtegaal I, de Wilt J; Dutch Liver Working Group. Hepatic resection for metastatic melanoma in The Netherlands: survival and prognostic factors. Melanoma Res 2013; 23:27–32.
Akyuz M, Yazici P, Dural C, Yigitbas H, Okoh A, Bucak E, et al. Laparoscopic management of liver metastases from uveal melanoma. Surg Endosc 2016; 30:2567–2571.
Hammond JS, Muirhead W, Zaitoun AM, Cameron IC, Lobo DN. Comparison of liver parenchymal ablation and tissue necrosis in a cadaveric bovine model using the Harmonic Scalpel™, the LigaSure™, the Cavitron Ultrasonic Surgical Aspirator® and the Aquamantys® devices. HPB 2012; 14:828–832.
Karydis I, Chan PY, Wheater M, Arriola E, Szlosarek PW, Ottensmeier CH. Clinical activity and safety of pembrolizumab in ipilimumab pre-treated patients with uveal melanoma. Oncoimmunology 2016; 5:e1143997.